Hopp til hovedinnhold

Trombofili

Sist revidert:
Sist revidert av:
  1. Moll S. Thrombophilia: clinical-practical aspects. J Thromb Thrombolysis. 2015 Apr;39(3):367-78. doi: 10.1007/s11239-015-1197-3. PMID: 25724822. PubMed  
  2. Federman DG, Kirsner RS. Rewiew article: An update on hypercoagulable disorders. Arch Intern Med 2001; 161: 1051-1056. PubMed  
  3. Roberts LN, Arya R. Hypercoagulable state. BMJ Best Practice, last updated August 2019.
  4. Bucciarelli P, Rosendaal FR, Tripodi A, et al: Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative family study. Arterioscler Thromb Vasc Biol 1999 Apr; 19(4): 1026-33. PubMed  
  5. Cushman M, O'Meara ES, Folsom AR, Heckbert SR. Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology. Blood 2009; 114: 2878. Blood  
  6. Baglin T, Gray E, Greaves M, et al; British Committee for Standards in Haematology. Clinical guidelines for testing for heritable thrombophilia. Br J Haematol. 2010;149:209-220. PubMed  
  7. Lidegaard Ø, Nielsen LH, Skovlund CW, et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 2011; 343: d6423. BMJ (DOI)  
  8. Majak P, Vikskjold F, Abildgaard U. Arvelig antitrombinmangel og graviditet - hva er effektiv tromboseprofylakse?. Tidsskr Nor Lægeforen 2003; 123: 144-6. Tidsskrift for Den norske legeforening  
  9. Pintao MC, Ribeiro DD, Bezemer ID, et al. Protein S levels and the risk of venous thrombosis: results from the MEGA case-control study. Blood 2013; 122: 3210-9 Blood  
  10. Meijers JCM, Tekelenburg WLH, Bouma BN, Bertina RM, Rosendal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med. 2000; 342: 696-701. PubMed  
  11. Levine JS, Branch DW, Rauch J: The antiphospholipid syndrome. N Engl J Med 2002 Mar 7; 346(10): 752-63. PubMed  
  12. Myones BL, McCurdy D: The antiphospholipid syndrome: immunologic and clinical aspects. Clinical spectrum and treatment. J Rheumatol 2000 Apr; 27 Suppl 58: 20-8.
  13. Wilson WA: Classification criteria for antiphospholipid syndrome. Rheum Dis Clin North Am 2001 Aug; 27(3): 499-505. PubMed  
  14. Greaves M. Antiphospholipid antibodies and thrombosis. The Lancet 1999; 353: 1348-53. The Lancet  
  15. Heegaard NHH, Locht H. Immunbetinget trombofili. Ugeskr Læger 2005; 167: 2861-4. PubMed  
  16. Norsk kvalitetsforbedring av laboratorieundersøkelser (Noklus). Anbefalte analyser ved ulike kliniske problemstillinger. Siden besøkt 01.10.2020. www.noklus.no  
  17. Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 2005; 293: 2352-61. Journal of the American Medical Association  
  • Terje Johannessen, professor i allmennmedisin, Trondheim

Tidligere fagmedarbeidere

  • Bjørnar Grenne, PhD, konst. overlege, Klinikk for hjertemedisin, St. Olavs Hospital, Trondheim
  • Odd Kildahl-Andersen, overlege, dr. med., Medisinsk avdeling, Universitetssykehuset Nord-Norge, Harstad sykehus